BCL2 and small cell lung carcinoma: Although BH3-mimetic Bcl2 inhibitors navitoclax and venetoclax have some antitumor efficacy in SCLC preclinical models 14, 15, phase I and phase II clinical studies of single-agent navitoclax achieved limited efficacy in SCLC patients 16, 17.